- Molecular NameVorinostat
- SynonymMK0683; N-hydroxy-n'-phenyloctanediamide; N-hyrdroxy-n'-phenyloctanediamide; SAHA; SHH; Suberanilohydroxamic acid; suberoylanilide hydroxamic acid; vorinostat
- Weight264.325
- Drugbank_IDDB02546
- ACS_NO149647-78-9
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)1.62
- pkaN/A
- LogD (pH=7, predicted)1.61
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-2.26
- LogSw (predicted, AB/LogsW2.0)0.49
- Sw (mg/ml) (predicted, ACD/Labs)1.46
- No.of HBond Donors3
- No.of HBond Acceptors5
- No.of Rotatable Bonds8
- TPSA78.43
- StatusFDA approved
- AdministrationN/A
- PharmacologyA member of a larger class of compounds that inhibit histone deacetylases (HDAC). Histone deacetylase inhibitors (HDI) have a broad spectrum of epigenetic activities.
- Absorption_valueN/A
- Absorption (description)Oral administration with a high-fat meal resulted in an increase (33%) in the extent of absorption and a modest decrease in the rate of absorption (Tmax delayed 2.5 hours) compared to the fasted state.
- Caco_2N/A
- Bioavailability43.0
- Protein binding71.0
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmThe major pathways of vorinostat metabolism involve glucuronidation and hydrolysis followed by ????-oxidation. Human serum levels of two metabolites, O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were measured. Both metabolites are pharmacologically inactive. Compared to vorinostat, the mean steady state serum exposures in humans of the O-glucuronide of vorinostat and 4-anilino-4-oxobutanoic acid were 4-fold and 13-fold higher, respectively. In vitro studies using human liver microsomes indicate negligible biotransformation by cytochromes P450 (CYP).
- Half life2 h
- ExcretionRenal (negligible)
- Urinary ExcretionN/A
- CleranceN/A
- ToxicityN/A
- LD50 (rat)N/A
- LD50 (mouse)N/A